Cargando…

"Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection

Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo-Aleman, Yandy M, Villegas-Valverde, Carlos A, Ventura-Carmenate, Yendry, Suarez-Formigo, Gisela M, Bencomo-Hernandez, Antonio A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756105/
https://www.ncbi.nlm.nih.gov/pubmed/36540317
http://dx.doi.org/10.7759/cureus.32548
_version_ 1784851561993732096
author Castillo-Aleman, Yandy M
Villegas-Valverde, Carlos A
Ventura-Carmenate, Yendry
Suarez-Formigo, Gisela M
Bencomo-Hernandez, Antonio A
author_facet Castillo-Aleman, Yandy M
Villegas-Valverde, Carlos A
Ventura-Carmenate, Yendry
Suarez-Formigo, Gisela M
Bencomo-Hernandez, Antonio A
author_sort Castillo-Aleman, Yandy M
collection PubMed
description Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-19) vaccines. This article aims to provide an immunological explanation for the delayed side effects of a SARS-CoV-2 vaccine during an episode of natural infection. We reported a case of a 39-year-old male healthcare worker who complained about pruritus and discomfort around the injection site of an inactivated SARS-CoV-2 vaccine administrated 18, 17, and 13 months earlier. Those symptoms resembled the side effects previously experienced with one of the booster doses, and a sole erythematous papule was also documented. The patient was diagnosed with COVID-19 one or two days after noticing these local signs and symptoms, and high serum titers of immunoglobulin M (IgM) and immunoglobulin E (IgE) were found five weeks after the onset, along with SARS-CoV-2-specific immunoglobulin G (IgG) antibodies. Therefore, the OAS might be a plausible phenomenon to consider in individuals immunized with inactivated vaccines and exposed secondarily to a wild virus with antigenic variations.
format Online
Article
Text
id pubmed-9756105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-97561052022-12-19 "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection Castillo-Aleman, Yandy M Villegas-Valverde, Carlos A Ventura-Carmenate, Yendry Suarez-Formigo, Gisela M Bencomo-Hernandez, Antonio A Cureus Internal Medicine Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-19) vaccines. This article aims to provide an immunological explanation for the delayed side effects of a SARS-CoV-2 vaccine during an episode of natural infection. We reported a case of a 39-year-old male healthcare worker who complained about pruritus and discomfort around the injection site of an inactivated SARS-CoV-2 vaccine administrated 18, 17, and 13 months earlier. Those symptoms resembled the side effects previously experienced with one of the booster doses, and a sole erythematous papule was also documented. The patient was diagnosed with COVID-19 one or two days after noticing these local signs and symptoms, and high serum titers of immunoglobulin M (IgM) and immunoglobulin E (IgE) were found five weeks after the onset, along with SARS-CoV-2-specific immunoglobulin G (IgG) antibodies. Therefore, the OAS might be a plausible phenomenon to consider in individuals immunized with inactivated vaccines and exposed secondarily to a wild virus with antigenic variations. Cureus 2022-12-15 /pmc/articles/PMC9756105/ /pubmed/36540317 http://dx.doi.org/10.7759/cureus.32548 Text en Copyright © 2022, Castillo-Aleman et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Castillo-Aleman, Yandy M
Villegas-Valverde, Carlos A
Ventura-Carmenate, Yendry
Suarez-Formigo, Gisela M
Bencomo-Hernandez, Antonio A
"Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
title "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
title_full "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
title_fullStr "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
title_full_unstemmed "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
title_short "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
title_sort "original antigenic sin" in sars-cov-2 vaccination followed by infection
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756105/
https://www.ncbi.nlm.nih.gov/pubmed/36540317
http://dx.doi.org/10.7759/cureus.32548
work_keys_str_mv AT castilloalemanyandym originalantigenicsininsarscov2vaccinationfollowedbyinfection
AT villegasvalverdecarlosa originalantigenicsininsarscov2vaccinationfollowedbyinfection
AT venturacarmenateyendry originalantigenicsininsarscov2vaccinationfollowedbyinfection
AT suarezformigogiselam originalantigenicsininsarscov2vaccinationfollowedbyinfection
AT bencomohernandezantonioa originalantigenicsininsarscov2vaccinationfollowedbyinfection